Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2016 - 2026)

Gyre Therapeutics has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $89.3 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4.99% to $89.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.3 million through Dec 2025, up 4.99% year-over-year, with the annual reading at $89.3 million for FY2025, 4.99% up from the prior year.
  • Shares Outstanding (Weighted Average) was $89.3 million for Q4 2025 at Gyre Therapeutics, up from $88.7 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $89.3 million in Q4 2025 and troughed at $28.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $63.6 million (2022), against an average of $60.0 million.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 3.53% in 2023 and then soared 126.32% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $30.6 million in 2021, then skyrocketed by 107.53% to $63.6 million in 2022, then increased by 3.53% to $65.8 million in 2023, then grew by 29.26% to $85.1 million in 2024, then increased by 4.99% to $89.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding (Weighted Average) are $89.3 million (Q4 2025), $88.7 million (Q3 2025), and $89.1 million (Q2 2025).